AbbVie Grows Gastrointestinal Business With Rinvoq Approval In UC

Along with Skyrizi’s expected approval in Crohn’s, AbbVie says Rinvoq in ulcerative colitis is key to its Humira sales erosion strategy. It is Rinvoq’s third US supplemental approval since December.

AbbVie building
AbbVie gets third supplemental FDA approval for Rinvoq in four months • Source: Alamy

AbbVie Inc. continues racking up indications for its JAK1 inhibitor, Rinvoq (upadacitinib), winning its fourth indication since the US Food and Drug Administration cleared it for rheumatoid arthritis in 2019. The drug moved into the gastrointestinal space on 16 March with a supplemental approval for ulcerative colitis, which followed FDA nods in December and January for psoriatic arthritis and atopic dermatitis, respectively.

AbbVie has talked up Rinvoq’s potential efficacy in inflammatory bowel disease (IBD) during recent investor presentations, with president Michael Severino...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip